N 5 (177) 2021. P. 23–31

THE EFFECT OF CYTOREDUCTIVE SURGERY AND INTRAPERITONEAL HYPERTHERMIC CHEMOPERFUSION ON THE CLINICAL OUTCOME OF TREATMENT OF PATIENTS WITH ADVANCED GASTRIC CANCER

V. M. Sokolov, O. V. Bondar, S. G. Chetverikov, V. Ye. Maksymovskyi, D. V. Atanasov, M. S. Chetverikov, V. V. Chetverikova-Ovchynnyk

Odesa National Medical University MH of Ukraine, Odesa, Ukraine

DOI 10.54229/2226-2008-2021-5-5

Introduction. For gastric cancer (GC), metastatic peritoneal carcinomatosis (PC) is a typical process. PC and its consequences usually lead to the death of 20–40% of patients with GC. For carefully selected patients, intraperitoneal hyperthermic chemoperfusion can be applied.

The aim of the study was to investigate the effect of cytoreductive surgery in combination with HIPEC on the clinical course of the postoperative period, the frequency of postoperative complications and side effects of chemotherapeutic drugs in the treatment of advanced GC.

Materials and methods. The results of treatment of 34 patients with advanced GC were analyzed. The patients were divided into two groups: IA group — 24 patients with advanced GC, who first underwent complete primary cytoreductive surgery (CRS) with adjuvant chemotherapy (ACT) according to the FLOT scheme and IB group — 10 patients with advanced GC treated by CRS + ACT + HIPEC.

Results. Comparing the number of patients with postoperative complications in groups IA (CRS + ACT) and IB (CRS + HIPEC + ACT) using the exact bilateral Fisher’s test p > 0.05. Comparing the frequency of side effects of chemotherapeutic treatment in the FLOT mode in groups IA (CRS + ACT) and IB (CRS + HIPEC + ACT), the values of c2 = 20.750, c2Cr = 28.568 (p = 0.0622) were obtained.

Conclusions. The usage of HIPEC in combination with complete CRS and ACT is a promising method of treatment of this group of patients. As a result of this study, it was proved that there is no statistically significant effect on the clinical course of the postoperative period due to the increase in the frequency of postoperative complications or side effects of chemotherapeutic drugs.

Key words: gastric cancer, cytoreductive surgery, HIPEC.

 

References

  1. Tazawa H, Suzuki T, Komo T, Kubota H, Tahara S, Sada H, et al. A Case of Advanced Gastric Cancer with Peritoneal Metastasis Treated Successfully with Nivolumab. Case Rep Oncol. 2019 Jul 16;12(2):523-528. DOI: 10.1159/000501717.
  2. Mura G, Verdelli B. The features of peritoneal metastases from gastric cancer. J Cancer Metastasis Treat. 2016;2:365-374. http://dx.doi.org/10.20517/2394-4722.2016.19.
  3. Sushkov OI., Achkasov SI. Peritoneal colorectal carcinomatosis. Approaches to treatment (review). Coloproctology. 2016;4(58):69-79.
  4. Dong XD. Right sided colon cancer and peritoneal carcinomatosis. Annals of Laparoscopic and Endoscopic Surgery. 2019;4:72–72. DOI: 10.21037/ales. 2019.07.10.
  5. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1-21. https://doi.org/10.1007/s10120-020-01042-y.
  6. Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. J Clin Oncol. 2019 Aug 10;37(23):2028-2040. DOI: 10.1200/JCO.18.01688.
  7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:gastric cancer (version 4.2021). 2021 Available from https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
  8. Ji ZH, Peng KW, Yu Y, Li XB, Yonemura Y, Liu Y, Sugarbaker PH, Li Y. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia 2017 Aug;33(5): 562-570. DOI: 10.1080/02656736.2017. 1283065.
  9. Ellison LM, Man Y, Stojadinovic A, Xin H, Avital I. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis. Chin J Cancer Res. 2017 Feb;29(1):86-92. DOI: 10 10.21147/j.issn.1000-9604.2017. 01.10.
  10. Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, Montori G, Ansaloni L. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015 Jul;41(7):911-9. DOI: 10.1016/j.ejso.2015.03.231.
View article PDF